.png){kind=icon}
Return
Know Thy PDX Model
.png){kind=icon}
OA
AI
DOI：10.1158/0008-5472.CAN-19-2023.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Patient-derived tumor xenograft (PDX) models are frequently used to study cancer mechanisms and potential therapeutics, however, differences in tumor evolution between models and patients have called into question their clinical relevance. In this issue, Mer and colleagues describe the Xenograft Visualization and Analysis (Xeva) software tool that empowers pharmacogenomic analysis through integration of PDX model tumor-drug response with genetic data. By performing the largest PDX model meta-analysis of its kind, the authors demonstrate PDX models are robust platforms for cancer treatment studies. With a clear need for more integrative studies, Xeva is well placed to make more important contributions to pharmacogenomic discovery.
Keywords:
XENOGRAFTS
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
16.6
Papers:
10.9W
Citations:
11.9W
Organization
Cited Papers
Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors.png)
CELLSOAAI
CELLSIF5.2
OAAIShareSaveShareSaveShareSaveShareSaveHigh-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseNATURE MEDICINE
NATURE MEDICINEIF50
PREAI
ShareSaveInterrogating open issues in cancer precision medicine with patient-derived xenograftsNATURE REVIEWS CANCEROAAI
NATURE REVIEWS CANCERIF66.8
OAAIShareSave no more
no more